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Cardiovascular diseases remain the most frequent cause of morbidity and mortality in patients with chronic kidney disease
(CKD). The aim of the study was to assess the association between oxidative stress biomarkers and cardiovascular risk factors
and left ventricular hypertrophy in children with CKD. Material and Methods. The studied group consisted of 65 patients aged
1.4–18.6 (mean 11.2) years with stages 1 to 5 CKD. Serum oxidized low-density lipoprotein (oxLDL), protein carbonyl group,
creatinine, cystatin C, albumin, lipids, high-sensitivity C-reactive protein, intercellular adhesion molecule-1, insulin, plasma renin
activity, and aldosterone levels were measured. Patients were divided into groups depending on CKD stage. Anthropometric
measurements, ambulatory blood pressure (BP)measurements, and echocardiographywith left ventricularmass (LVM) calculation
were performed. Results. Serum oxLDL strongly correlated with creatinine (𝑅 = 0.246; 𝑝 = 0.048), cystatin C (𝑅 = 0.346;
𝑝 = 0.006), total cholesterol (𝑅 = 0.500; 𝑝 < 0.001), triglycerides (𝑅 = 0.524; 𝑝 < 0.001), low-density lipoprotein concentrations
(𝑅 = 0.456; 𝑝 < 0.001), and 24 hour BP values of systolic (𝑅 = 0.492; 𝑝 = 0.002), diastolic (𝑅 = 0.515; 𝑝 < 0.001), and mean
arterial pressure (𝑅 = 0.537; 𝑝 < 0.001). A significant correlation between oxLDL levels and LVM 𝑧-scores (𝑅 = 0.299; 𝑝 = 0.016)
was found. Conclusions. Hypertension and dyslipidemia correlated with lipid oxidation in children with CKD. oxLDLs seem to be
valuable markers of oxidative stress in CKD patients, correlating with left ventricular hypertrophy.
1. Introduction
An imbalance between the processes of formation of free
radicals and their removal with a predominance of the
production of reactive oxygen species (ROS) is referred
to as oxidative stress. The uncontrolled increase in the
concentration of free radicals is postulated to be one of the
pathophysiological mechanisms of many diseases such as
diabetes, atherosclerosis, vascular dementia, or neoplasms.
Under physiological conditions, ROS and reactive nitrogen
species (RNS) are constantly produced to defend the body
against germs and are also of importance in the processes of
cell signaling, tissue healing, and remodeling [1]. ROS include
superoxide radical, hydrogen peroxide, and hydroxyl radical.
The role of antioxidants in the body is fulfilled by enzymes:
superoxide dismutase, catalase, oxidase, and glutathione per-
oxidase, and other substances such as glutathione, vitamins E
and C, magnesium ions, zinc, albumin, ferritin, transferrin,
and uric acid.
In patients with chronic kidney disease (CKD) treated
conservatively and on dialysis, both the increased production
of ROS and RNS and reduced antioxidant status have been
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shown [2, 3]. Activation of the renin-angiotensin-aldosterone
and sympathetic systems, as well as chronic inflammation,
results in the production of oxidative stress markers. Low-
density lipoprotein particle modified in the process of oxida-
tion (oxLDL) develops atherogenic properties and becomes
cytotoxic to vascular endothelial cells, stimulates the growth
of smooth muscle, and attracts macrophages. oxLDL also
inhibits macrophage mobility favoring their accumulation
and formation of fatty streaks—the initial stage of the
atherosclerotic process [4–6].
Oxidative stress is considered to be one of the cardio-
vascular risk factors in patients with CKD. In this group of
patients higher prevalence of traditional risk factors (hyper-
tension, dyslipidemia) and uremia-related ones (chronic
inflammation, oxidative stress, endothelial dysfunction, ane-
mia, fluid overload, anduremia toxins) is found.Many studies
have shown increased morbidity and mortality from cardio-
vascular causes in adults with CKD. In children, because
hard endpoints, such as stroke or cardiovascular death, are
rarely evaluated, surrogate endpoints, such as left ventricular
hypertrophy (LVH), are more frequently observed [7].
The aim of the studywas to assess the association between
oxidative stress biomarkers and cardiovascular risk factors
and left ventricular hypertrophy in children with chronic
kidney disease.
2. Material and Methods
Medical examinations were carried out from June 2008 to
February 2011. The study was performed in accordance with
the Declaration of Helsinki of 1975 for Human Research and
approved by the Bioethical Committee of the Jagiellonian
University (KBET/17/B/2006). The parents and patients were
informed about the objective and method of performing the
study and gave their informed consent.
2.1. Subjects. The inclusion criterionwas the age of 0–21 years
and diagnosed chronic kidney disease. The exclusion criteria
were lack of consent of the patient or parents, congenital heart
defects or other primary heart diseases, acute infections, or
failure of other organs.
2.2. Blood Sampling and Biochemical Analysis. On admission
blood samples were taken from all patients (fasting for 12
hours). Three samples were collected and centrifuged and
plasma and serum were frozen at −80∘C. Biochemical anal-
yses necessary to determine kidney function were performed
and urea, creatinine, cystatin C, electrolytes, albumin, aldos-
terone, and lipids concentrations were measured; plasma
renin activity (PRA) was assessed. On the basis of serum
creatinine and cystatin C, an estimated glomerular filtration
rate (eGFR) with the Schwartz [8] and Filler [9] formulas was
calculated. Patients were divided into groups depending on
the stage of CKD [group 1: CKD stages 1 + 2 (GFR > 60),
group 2: CKD stage 3 (GFR = 30–59), group 3: CKD stage 4
(GFR = 15–29mL/min/1.73m2), group 4: dialyzed children].
To assess oxidative stress the concentration of oxidized
LDL particles, as an effect of lipid oxidation, and the con-
centration of carbonyl groups resulting from oxidation of
proteins were used. Concentrations of serum high sensitive
C-reactive protein (hsCRP) (R&D Systems, USA); oxLDL
(Mercodia Inc., Sweden); protein carbonyl groups (Cay-
man Chemical Company, USA); and intercellular adhesion
molecule-1 (ICAM-1) (R&D Systems, USA) were determined
with enzyme-linked immunosorbent assay (ELISA). Insulin
levels (BioSource, Belgium) were measured using the IRMA
method.
2.3. Anthropometric and Blood Pressure Measurements. Dur-
ing each visit, anthropometric parameters of patients, weight,
height, and waist circumference, were measured. BMI was
calculated by dividing weight in kilograms by height in
meters squared. 24 h blood pressure monitoring (ambulatory
blood pressuremeasurement, ABPM) using SpaceLabs 90207
device and cuff of appropriate size was performed. Blood
pressure measurements were taken in an interval of 20
minutes during the day and every 30 minutes during the
night. With the help of a licensed ABPM program mean
values of systolic (SBP), diastolic (DBP), and mean blood
pressure (mean arterial pressure, MAP) for the whole day
were calculated. Hypertension was defined as BP values equal
to or exceeding the 95th percentile for gender, age, and
height [10]. The absolute values of height, weight, and BMI
measurements were converted to 𝑧-scores based on data
published by Palczewska and Niedźwiecka [11].
2.4. Left Ventricular Hypertrophy Assessment. Echocardio-
graphic examinations were performed by an experienced
cardiologist using HP 5500 unit with S4 and S8 variable
frequency probes. In children on chronic hemodialysis
echocardiography was performed on the day between two
hemodialysis procedures, while in children on peritoneal
dialysis, it was performed during the daily exchange, with a
low volume of dialysate in the peritoneal cavity.
Left ventricular end-diastolic dimension (LVEDd), inter-
ventricular septal thickness at end diastole (IVSd), and left
ventricular posterior wall thickness at end diastole (LVPWd)
were measured by 2-dimensional guided M-mode echocar-
diography using the parasternal short-axis view at the level
of the papillary muscles. Diameters and thickness were
corrected for body surface area (BSA) and normal ranges
were assessed according to values published by Kampmann
et al. [12].
LV mass (LVM) was calculated by the formula described
by Devereux and Reichek [13]. LVM 𝑧-score for height was
calculated according to the method described by Foster et al.
[14]. LVM index (LVMI) was obtained by dividing LVM by
height2.7 to normalize and linearize the relationship between
LVM and height [15]. LV hypertrophy (LVH) was diagnosed
when LVMI was over the 95th percentile for healthy children
[16]. We used age-specific cut-off values provided by Khoury
et al. [17].
2.5. Statistical Analysis. Qualitative values were compared
by the chi-square test. Because data of the majority of
variables did not show normal distribution, they are pre-
sented asmedian [25th–75th percentile]. Differences between
the groups were compared using the Kruskal-Wallis test.
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Spearman’s rank correlationwas used to relate levels of kidney
function and oxidative stress markers. Statistical calculations
were performed using a commercially available statistical
package (Statistica PL). A value of 𝑝 < 0.05 was considered
significant in all statistical analyses.
3. Results
The studied group consisted of 65 patients (41 boys and 24
girls) aged 1.4 to 18.6 (mean 11.2) years with stage 1 to stage
5 CKD, who were under constant medical control in the
University Children’s Hospital in Krakow. Among diseases
leading to the development of CKD in the examined children,
the highest prevalence was noted in congenital abnormalities
of the kidney and urinary tract, 31 (47.7%), followed by
glomerulonephritis, 8 (12.3%), cystic disease, 7 (10.8%), and
others, 19 (29.2%).
Clinical data and basic kidney function parameters
depending on the stage of chronic kidney disease are pre-
sented in Table 1.
Several parameters of possible mechanisms (PRA, aldos-
terone, endothelial dysfunction-ICAM-1, inflammation-
hsCRP, and hyperinsulinism) associated with oxidative
stress were analyzed according to CKD stage in the studied
group. There was a significant difference in median oxLDL
concentration between CKD stages 3 and 5 (75.81 versus
98.89U/L; 𝑝 = 0.019). There were no significant differences
in the concentration of most evaluated parameters (Table 2).
In the studied group 41 out of 65 patients were treated
with angiotensin-converting enzyme inhibitors (ACEI) or
angiotensin receptor blocker (ARB), 63.6% in stages 1 + 2,
72.2% in stage 3, 64.3% in stage 4, and 54.5% in stage 5,
respectively. There were no differences between children on
ACEI or ARB and without this treatment (data on request).
The average concentration of oxidized LDLwas 86.94U/L
and of carbonyl groups 1.69 nmol/mg. Elevated concen-
trations of protein carbonyl groups (>4 nmol/mg) were
observed in 6 of 54 patients. The median oxLDL concentra-
tionwas significantly higher in girls than in boys (99.86 versus
81.06U/L; 𝑝 = 0.024).
In the studied population there was no correlation
between oxLDL and age, CKD duration, weight, body
mass index (BMI) in 𝑧-score, urea, high-density lipoprotein
(HDL), albumin, insulin, hsCRP and ICAM-1, and aldos-
terone concentrations. Correlations of investigated param-
eters (aldosterone, PRA, carbonyl group, oxLDL, ICAM-
1, hsCRP, and insulin) with kidney function markers were
performed. The most pronounced correlations were found
for oxLDL: its concentration significantly correlated with
creatinine (𝑅 = 0.246; 𝑝 = 0.048), cystatin (𝑅 = 0.346;
𝑝 = 0.006), and eGFR calculated on their basis (𝑅 = −0.266;
𝑝 = 0.032 and 𝑅 = −0.296; 𝑝 = 0.027, resp.). Furthermore
oxLDL strongly correlated with total cholesterol (𝑅 = 0.500;
𝑝 < 0.001), TGL (𝑅 = 0.524; 𝑝 < 0.001), LDL (𝑅 =
0.446; 𝑝 < 0.001), and 24 hour blood pressure values of SBP
(𝑅 = 0.492; 𝑝 = 0.002), DBP (𝑅 = 0.515; 𝑝 < 0.001), and
MAP (𝑅 = 0.537; 𝑝 < 0.001) and negatively with PRA (𝑅
= −0.264; 𝑝 = 0.038). hsCRP correlated significantly with
40 60 80 100 120 140 160 180 20020
oxLDL (U/L)
−3
−2
−1
0
1
2
3
4
5
6
7
LV
M
 (z
-s
co
re
)
Figure 1: Scatterplot presenting the correlation between oxLDL
concentrations and left ventricular mass (LVM) (𝑧-score).
creatinine (𝑅 = 0.266; 𝑝 = 0.033), while insulin correlated
with creatinine (𝑅 = 0.333; 𝑝 = 0.009) and cystatin C
(𝑅 = 0.337; 𝑝 = 0.010) concentrations and eGFR calculated
with the Filler formula (𝑅 = −0.422; 𝑝 = 0.002).
Patients were divided into 4 groups depending on the
quartiles of oxLDL concentration and clinical, biochemical,
and echocardiographic parameters between groups were
compared. Children with high oxLDL concentrations were
characterized by significantly higher blood pressure, triglyc-
erides, and total and LDL cholesterol levels. In this group also
higher left ventricular mass was found (Table 3).
Echocardiographic examinations revealed LVH in 34
children.There were no significant differences inmedian car-
bonyl groups concentrations between childrenwith andwith-
out LVH (1.17 (0.62; 1.89) versus 1.29 (0.85; 1.96) nmol/mg;
𝑝 = 0.567). A trend toward higher median oxLDL values in
children with LVH was present (88.60 (76.24; 107.07) versus
81.06 (61.13; 98.35)U/L; 𝑝 = 0.084), although it did not reach
statistical significance.
There was a significant correlation between oxLDL con-
centration and LVPWT (𝑧-score) (𝑅 = 0.258; 𝑝 = 0.038).
In the univariate analysis, LVM in 𝑧-scores correlated signif-
icantly with eGFR (𝑅 = −0.427; 𝑝 = 0.001), MAP (𝑧-score)
(𝑅 = 0.487; 𝑝 = 0.002), albumin (𝑅 = −0.363; 𝑝 = 0.004), and
oxLDL concentrations (𝑅 = 0.299; 𝑝 = 0.016) (Figure 1). In
the multivariate analysis, the single independent parameter
was MAP (𝐵 = 0.383; 𝑝 = 0.001). After exclusion of MAP
from the equation 3 parameters correlated independently
with LVM 𝑧-score (eGFR: 𝐵 = −0.01; 𝑝 = 0.034; albumin:
𝐵 = −0.025; 𝑝 = 0.047; and oxLDL: 𝐵 = 0.023; 𝑝 = 0.001).
4. Discussion
This is, to our knowledge, the first study comparing oxidative
stress markers and left ventricular hypertrophy in children
with chronic kidney disease.
Despite the enormous technological progress and the
introduction of new medications into the treatment of
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Table 1: Basic clinical data and kidney function parameters depending on CKD stage in the investigated group of 65 patients.
Parameter
CKD stage
𝑝 value1 + 2
(𝑛 = 11)
3
(𝑛 = 18)
4
(𝑛 = 14)
5
(𝑛 = 22)
Age (years) 10.51(5.04; 16.08)
11.33
(5.15; 16.33)
12.01
(8.70; 15.99)
11.61
(8.51; 15.20) 0.820
Height (𝑧-score)∗ 0.078(−0.300; 0.569)
−0.716
(−2.303; 0.060)
−0.868
(−1.484; −0.210)
−1.495
(−3.444; −0.130) 0.013
Body mass (𝑧-score)∗∗ −0.015(−0.409; 0.419)
−0.980
(−1.635; 0.009)
−0.464
(−1.054; 0.228)
−1.587
(−3.714; −0.828) 0.002
BMI (kg/m2) 16.5(15.8; 22.1)
16.6
(14.7; 19.5)
18.1
(16.0; 20.4)
15.9
(14.5; 17.2) 0.224
BMI (𝑧-score)∗∗∗ 0.316(−0.318; 0.712)
−0.779
(−1.636; 0.433)
0.079
(−0.638; 0.712)
−1.252
(−1.599; −0.621) 0.020
Creatinine (𝜇mol/L)∗∗∗∗ 69.3(34.0; 93.8)
113.8
(95.0; 146.4)
274.9
(203.8; 311.9)
501.8
(414.3; 869.0) <0.001
Cystatin C (mg/L)∗∗∗∗ 0.86(0.68; 1.23)
1.45
(1.17; 1.86)
2.6
(2.23; 3.01)
4.81
(4.14; 6.53) <0.001
eGFR Filler∗∗∗∗(mL/min/1.73m2) 109.46(72.62; 141.28)
60.13
(45.64; 76.81)
29.49
(26.19; 36.49)
14.77
(9.78; 18.43) <0.001
Values presented as median (25th–75th percentile).
BMI—body mass index; eGFR—estimated glomerular filtration rate.
∗Statistically significant differences between stages 1 + 2 and 4, 1 + 2 and 5.
∗∗Statistically significant differences between stages 1 + 2 and 3, 1 + 2 and 5, 4 and 5.
∗∗∗Statistically significant differences between stages 4 and 5.
∗∗∗∗Statistically significant differences between all stages.
Table 2: Selected parameters depending on CKD stage in the investigated group of 65 patients.
Parameter
CKD stage
𝑝 value1 + 2
(𝑛 = 11)
3
(𝑛 = 18)
4
(𝑛 = 14)
5
(𝑛 = 22)
hsCRP (ng/mL) 171.6(128.7; 464.3)
252.4
(106.5; 2574.9)
338.9
(143.0; 771.6)
365.6
(187.2; 878.1) 0.397
Carbonyl groups (nmol/mg) 1.15(0.54; 1.32)
1.24
(0.87; 1.69)
1.64
(0.73; 2.41)
1.23
(0.66; 2.05) 0.454
oxLDL (U/L)∗ 80.65(60.56; 109.68)
75.81
(56.66; 97.87)
82.31
(75.48; 91.92)
98.89
(82.16; 108.73) 0.030
Aldosterone (pg/mL) 186.1(103.5; 298.7)
272.8
(142.3; 662.1)
471.00
(169.0; 1073.1)
192.3
(86.4; 711.4) 0.250
PRA (ng/mL/h) 4.99(1.25; 8.38)
6.88
(3.41; 12.51)
4.69
(1.64; 9.98)
3.88
(2.01; 7.94) 0.521
ICAM-1 (ng/mL) 305.7(289.4; 354.3)
319.1
(291.8; 446.3)
322.1
(290.3; 337.7)
329.2
(267.3; 408.9) 0.922
Insulin (𝜇IU/mL) 9.0(7.0; 10.6)
9.5
(8.1; 15.7)
12.8
(10.1; 16.8)
13.1
(6.9; 16.3) 0.162
Albumin (g/L) 45.0(41.0; 47.0)
45.50
(41.0; 47.5)
46.8
(45.0; 49.1)
44.1
(37.7; 47.1) 0.127
Values presented as median (25th–75th percentile)
hsCRP—high sensitive C-reactive protein; oxLDL—oxidized low-density lipoprotein; PRA—plasma renin activity; ICAM-1—intercellular adhesion molecule-
1.
∗Statistically significant differences between stages 3 and 5.
patients with impaired renal function, this group is charac-
terized by an increased cardiovascular risk. Mortality asso-
ciated with cardiovascular causes is higher in children and
adults with CKD compared to the general population [18].
According to data from the USA, the estimated survival time
of children on dialysis is 40–60 years shorter than healthy
peers [19].
CKD patients are exposed to high prevalence of tradi-
tional cardiovascular risk factors as well as nontraditional
ones, such as inflammation, oxidative stress, and endothelial
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Table 3: Investigated clinical, biochemical, and echocardiographic parameters in the groups with oxLDL quartiles.
Parameter
oxLDL (U/L)
𝑝 value41.4–67.4
(𝑛 = 16)
67.5–84.8
(𝑛 = 17)
86.0–103.5
(𝑛 = 16)
103.6–176.1
(𝑛 = 16)
SBP 24 h (𝑧-score) 0.11(−2.64; 0.53)
−0.62
(−0.92; 0.56)
−0.33
(−1.41; 1.30)
1.86
(1.03; 2.73) 0.009
DBP 24 h (𝑧-score) −0.06(−1.80; 0.27)
−0.77
(−2.14; 1.37)
−0.46
(−1.40; 1.78)
2.42
(1.16; 4.64) 0.004
MAP 24 h (𝑧-score) 0.42(−1.82; 0.79)
−0.32
(−1.09; 1.04)
0.00
(−0.86; 1.76)
2.32
(2.01; 4.45) 0.003
Total chol. (mmol/L) 4.19(3.63; 4.81)
4.48
(4.13; 5.01)
4.67
(4.08; 5.62)
6.19
(5.39; 7.50) 0.001
TGL (mmol/L) 1.21(0.90; 1.62)
1.30
(1.08; 1.47)
1.69
(1.28;2.35)
2.62
(1.63; 3.70) 0.001
HDL (mmol/L) 1.35(1.08; 1.76)
1.35
(1.17; 1.76)
1.19
(1.03;1.43)
1.26
(0.97; 1.62) 0.417
LDL (mmol/L) 2.07(1.70; 2.59)
2.43
(1.99; 2.64)
2.49
(2.08; 3.39)
3.26
(2.57; 4.01) 0.005
Cystatin (mg/L) 1.36(1.09; 2.97)
2.36
(1.17; 3.46)
2.55
(1.61; 4.07)
4.24
(1.48; 6.12) 0.053
Albumin (g/L) 46.0(44.1; 48.0)
46.0
(44.0; 47.7)
45.0
(38.3; 47.0)
43.0
(34.0; 47.6) 0.320
hsCRP (ng/mL) 267.5(159.5; 688.2)
321.9
(162.5; 553.4)
459.2
(104.3; 1270.2)
273.2
(121.5; 486.4) 0.939
ICAM-1 (ng/mL) 295.5(267.3; 339.4)
303.0
(288.5; 346.4)
339.9
(316.0; 405.8) 326.4 (278.4; 396.7) 0.373
Carbonyl groups (nmol/mg) 1.39(0.87; 1.69)
1.73
(0.50; 2.25)
1.23
(0.96; 1.87)
0.92
(−0.54; 1.75) 0.736
LVM (𝑧-score) 0.05(−1.06; 0.76)
−0.27
(−0.99; 0.64)
0.73
(−0.41; 1.70)
1.01
(−0.05; 2.61) 0.038
LVEDd 𝑧-score 0.17(−0.61; 0.85)
0.19
(−0.19; 0.61)
−0.03
(−0.60; 0.57)
0.22
(−0.31; 0.83) 0.765
IVSd 𝑧-score 0.99(.07; 1.42)
0.31
(−0.06; 0.93)
1.06
(0.18; 1.72)
1.08
(0.56; 2.07) 0.082
LVPWT 𝑧-score 0.75(0.18; 1.40)
1.32
(0.26; 1.58)
1.40
(0.50; 2.19)
1.45
(0.65; 2.37) 0.281
Values presented as median (25th–75th percentile).
SBP 24 h—systolic blood pressure 24 h; DBP 24 h—diastolic blood pressure 24 h; MAP 24 h—mean arterial pressure 24 h; TGL—triglycerides; HDL—
high-density lipoprotein; LDL—low-density lipoprotein; hsCRP—high sensitive C-reactive protein; oxLDL—oxidized low-density lipoprotein; ICAM-1—
intercellular adhesion molecule-1; LVM—left ventricular mass; LVEDd—left ventricular end-diastolic dimension; IVSd—interventricular septum at end
diastole; LVPWd— left ventricular posterior wall thickness at end diastole.
dysfunction. These factors are responsible for accelerated
atherosclerosis and heart damage. Fruchart et al. proposed
a division of atherosclerosis risk factors into the old, the
old/new, and the new [20]. The authors included into new
agents, among others, triglycerides, oxidized LDL and anti-
oxidized LDL antibodies, lipoprotein (a), homocysteine, and
hsCRP, which indicates the role of oxidative stress and
inflammation in atherosclerosis. Numerous studies [21–24]
have shown increased concentrations of oxidative stress
markers, such as advanced products of protein oxidation,
malondialdehyde, and isoprostanes in patients with chronic
kidney disease. Children on dialysis have demonstrated
reduced antioxidant enzymes activity and decreased levels of
trace elements [25]. According to different authors, oxidative
stress plays a central role in the development and accelerated
progression of atherosclerosis in patients with impaired renal
function [23].
Our data suggest that uremia per se is a significant
contributor to oxidative stress. In the studied group of
children with chronic kidney disease a significant correlation
between the concentrations of oxidized LDL and serum
creatinine and cystatin C was demonstrated. The highest
median concentration of oxLDLs was found in the group
of children undergoing dialysis. Furthermore, a significant
influence of traditional cardiovascular risk factors, hyper-
tension and lipid disturbances, on the severity of oxidative
stress in childrenwithCKDwas shown. oxLDL concentration
correlated strongly with 24 hour systolic, diastolic, and mean
arterial pressure values and with total cholesterol, triglyc-
erides, and LDL cholesterol levels. The lack of correlation
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between kidney function impairment and aldosterone level as
well as plasma renin activity is probably connected with wide
use of nephroprotection, starting at the early stage of chronic
kidney disease. From the studied population 63% of children
were treated with ACEI or ARB.
Statins are becoming more widely used in children,
especially in those with familial hypercholesterolemia [26].
Given the high cardiovascular risk in patients with CKD and
lack of efficacy of dietary restrictions in lipid normalization,
it seems reasonable to execute clinical trials and determine
the indications for statin therapy in these children and
adolescents. A few recent studies have demonstrated that
the use of statins may not only inhibit cholesterol synthesis
but also have important pleiotropic effects, such as antiox-
idant and cytoprotective abilities. In the study of Chang et
al. a significant reduction in CRP levels after 8 weeks of
simvastatin therapy was observed in hemodialysis patients,
which reflects the anti-inflammatory effect of statins [27].
In the study by Kumar et al., in a retrospective analysis of
257 dialyzed patients, the relation between statin therapy
and lower CRP levels was found [28]. Furthermore, in
another study a significant relationship between statin use
and reduction of IL-6 levels was identified [29]. The result
of anti-inflammatory effect of statins treatment may exceed
beyond their lipid lowering effect in patients with CKD, but
there is insufficient data for the pediatric population.
Over the last decades, several research studies investigat-
ing the role of oxidative stress in chronic kidney disease in
adults were undertaken [30]. Müller et al. examining DNA
damage showed a significantly higher degree of oxidative
stress in hemodialyzed patients, compared to healthy volun-
teers [31]. Kaneda et al. found elevated AOPP concentrations
in patients with ischemic heart disease and in those treated
with hemodialysis. It should be pointed out that the severity
of coronary heart disease correlated with AOPP quartiles
[32]. In hemodialyzed patients the concentration of malondi-
aldehyde (MDA)—ameasure of lipid peroxidation—was sig-
nificantly higher than that in patients with CKD treated con-
servatively and healthy subjects [33]. On the other hand, the
concentration of an antioxidant—superoxide dismutase—
was reduced. The combination of increased oxidative stress
and lipid disorders leads to the progression of the process
of atherosclerosis in patients with chronic kidney disease.
Sakata and colleagues found an increased accumulation of
advanced glycation end products in atherosclerotic lesions—
from intimal thickening to atherosclerotic plaque—in the
aorta of people with end-stage renal disease [34]. In the post-
mortem examination of aorta sections an increased content
of pentosidine and MDA in the fraction of elastin in patients
on hemodialysis was detected. The modification of elastin in
the processes of glycoxidation and lipid peroxidation could
lead to vascular lesions exaggeration in patients with end-
stage renal disease [35].
The main factor influencing the increase in left ven-
tricular mass in our study was elevated blood pressure.
Several other parameters such as high oxLDL, low albumin
concentrations, and low eGFR also correlated with LVM.
The studied group of children with high oxLDL levels had
significantly higher LVM and left ventricular posterior wall
thickness. Future studies are needed to evaluate oxLDL as a
biomarker of oxidative stress target organ damage in children.
Holvoet et al. proposed evaluating the concentration of
circulating oxidized LDLs as means of a more accurate
cardiovascular risk assessment. Adults with coronary artery
disease confirmed in angiography had significantly higher
concentrations of oxLDLs. A significant correlation between
oxLDLs and most of Framingham risk factors was also
demonstrated [36]. In hemodialyzed patients, particularly
vulnerable to oxidative stress, a beneficial effect of antioxidant
usage in the form of large vitamin E doses on secondary
prevention was shown in the SPACE study [37]. Treatment
with vitamin E for a period of about two years reduced the
risk of myocardial infarction, ischemic stroke, and peripheral
vascular disease. The supply of a different antioxidant (N-
acetyl-cysteine) led to a reduction in intracellular oxidative
stress and the incidence of apoptosis in T cells in children on
chronic hemodialysis [38].
In the studied population a significant correlation
between hsCRP and serum creatinine concentrations was
found. It should be stressed out that in children recorded
hsCRP concentrations did not exceed 3mg/L, a value that
indicates an increased cardiovascular risk associated with the
severity of chronic inflammation. In adults on hemodialysis
significantly higher concentration of carbonyl groups in
comparison to healthy subjects was observed. Danielski and
coauthors suggested that increased oxidative stress associated
with inflammation and phagocytic cell activation might
preferentially increase aldehyde formation and oxidize thiol
groups in proteins rather than promote lipid peroxidation
[39]. In adults with diabetes mellitus protein carbonyl (PCO)
content was higher than that in healthy controls and the
hemodialysis procedure caused additional elevation of PCO
levels [40]. The lack of a significant increase in protein
carbonyl content in children with advanced CKD compared
to adults can result from various diseases leading to impaired
renal function. In adults, the most common causes of CKD
are diabetes mellitus and long-lasting hypertension and in
children, congenital abnormalities of kidney and urinary
tract. In our study there was no correlation between insulin
and oxLDL concentrations.
Chronic kidney disease is frequently accompanied by
decreased albumin levels, both in adults and in children [41,
42]. Serum albumin concentration was found to be an inde-
pendent predictor ofmortality risk in a broad range of clinical
and research settings in adults [43], especially in those with
end-stage renal disease [44]. This increase in mortality was
independent of malnutrition, a condition that until recently
was thought to be the reason for reduced albumin levels
[44]. Albumin is postulated to be major and predominant
circulating antioxidant [45]. Several researchers have eval-
uated the relation between hypoalbuminemia and oxidative
stress in adults with CKD; however no data is available for
the pediatric population. Levels of inflammatory and oxida-
tive stress biomarkers were increased in hypoalbuminemic
compared with normoalbuminemic end-stage renal disease
adults undergoing hemodialysis in a study by Danielski et al.
[39]. Kaneko and coauthors found significantly lower serum
levels of biological antioxidant potentials in adults with
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idiopathic nephrotic syndrome [46]. In our study we found
no correlation between albumin and oxLDL concentrations.
Low albumin is related to overhydration and, as a result, high
blood pressure [42] and left ventricular hypertrophy [47].
We demonstrated a significant negative correlation between
albumin concentration and left ventricular mass expressed in
𝑧-score.
In the early stages of the atherosclerotic process there is an
activation of adhesion molecules, which promotes adhesion
of monocytes to the vascular wall and their migration to
the intima. As a result of chronic inflammation adhesion
molecules belonging to the immunoglobulin family: ICAM-
1 (intercellular adhesion molecule-1) and VCAM-1 (vascular
adhesion molecule-1) are being expressed on endothelial
cells. In the work of Ridker et al. the growing concentration
of soluble ICAM-1 adhesion molecule was one of the major
cardiovascular risk factors in postmenopausal women and
the risk increased 2.6-fold between the lowest and highest
quartiles of ICAM-1 levels [48]. In the studied population of
children with CKD, no influence of the degree of renal func-
tion impairment on plasma ICAM-1was found. Furthermore,
no correlation of ICAM-1 with oxidative stress biomarkers
was shown.
5. Conclusions
In children with chronic kidney disease an increase in the
concentration of oxidized LDLs with the progression of
the disease was found. This biomarker of oxidative stress
was strongly correlated with 24 hour blood pressure values,
triglycerides, and total and LDL cholesterol levels. Oxidized
LDLs seem to be valuable markers of oxidative stress in
CKD patients, correlating with left ventricular hypertrophy.
In contrast to adults, the protein carbonyl content did not
increase in advanced stages of CKD.
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[18] I. Zagożdżon, A. Żurowska, S. Prokurat et al., “Do children with
end-stage renal disease live shorter? Analysis of mortality on
the basis of data from the Polish Registry of Renal Replacement
Therapy in Children,” Advances in Medical Sciences, vol. 60, no.
1, pp. 13–17, 2015.
[19] National Kidney Foundation Task Force on Cardiovascular
Disease, “Controlling the epidemic of cardiovascular disease
in chronic renal disease: what do we know? What do we need
to know? Special report from the National Kidney Foundation
Task Force on Cardiovascular Disease,” American Journal of
Kidney Diseases, vol. 32, no. 3, pp. 1–121, 1998.
[20] J.-C. Fruchart, M. C. Nierman, E. S. G. Stroes, J. J. P. Kastelein,
and P. Duriez, “New risk factors for atherosclerosis and patient
risk assessment,” Circulation, vol. 109, no. 23, supplement 1, pp.
15–19, 2004.
[21] C.-C. Sung, Y.-C. Hsu, C.-C. Chen, Y.-F. Lin, and C.-C.
Wu, “Oxidative stress and nucleic acid oxidation in patients
with chronic kidney disease,” Oxidative Medicine and Cellular
Longevity, vol. 2013, Article ID 301982, 15 pages, 2013.
[22] P. S. Tucker, V. J. Dalbo, T. Han, andM. I. Kingsley, “Clinical and
research markers of oxidative stress in chronic kidney disease,”
Biomarkers, vol. 18, no. 2, pp. 103–115, 2013.
[23] N.-A. Le and E. O. Gosmanova, “Cardiovascular complications
in CKD patients: Role of oxidative stress,” Cardiology Research
and Practice, vol. 2011, Article ID 156326, 8 pages, 2011.
[24] A. Remppis and E. Ritz, “Cardiac problems in the dialysis
patient: beyond coronary disease,” Seminars in Dialysis, vol. 21,
no. 4, pp. 319–325, 2008.
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[42] D. Drożdż, P. Korohoda, J. A. Pietrzyk et al., “Nutritional
and volemic status evaluated by bioimpedance analysis in
peritoneally dialysed children. Polishmulticenter study results,”
Standardy Medyczne Pediatria, vol. 4, no. 1, pp. 55–59, 2007.
[43] P. Goldwasser and J. Feldman, “Association of serum albumin
andmortality risk,” Journal of Clinical Epidemiology, vol. 50, no.
6, pp. 693–703, 1997.
[44] B. A. Cooper, E. L. Penne, L. H. Bartlett, and C. A. Pollock,
“Protein malnutrition and hypoalbuminemia as predictors of
vascular events and mortality in ESRD,” American Journal of
Kidney Diseases, vol. 43, no. 1, pp. 61–66, 2004.
[45] M. Roche, P. Rondeau, N. R. Singh, E. Tarnus, and E. Bourdon,
“The antioxidant properties of serum albumin,” FEBS Letters,
vol. 582, no. 13, pp. 1783–1787, 2008.
[46] K. Kaneko, T. Kimata, S. Tsuji, T. Shimo, M. Takahashi, and S.
Tanaka, “Serum albumin level accurately reflects antioxidant
potentials in idiopathic nephrotic syndrome,” Clinical and
Experimental Nephrology, vol. 16, no. 3, pp. 411–414, 2012.
[47] F. Raimondi, M. Chinali, D. Girfoglio et al., “Inappropriate left
ventricular mass in children and young adults with chronic
renal insufficiency,” Pediatric Nephrology, vol. 24, no. 10, pp.
2015–2022, 2009.
[48] P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai,
“C-reactive protein and other markers of inflammation in
the prediction of cardiovascular disease in women,” The New
England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000.
